What is the appropriate treatment for transverse low‑grade colitis in an adult?

Treatment for Transverse Low-Grade Colitis

For transverse low-grade colitis (representing extensive mild-to-moderate ulcerative colitis), initiate high-dose oral 5-aminosalicylate (5-ASA) at >3g/day combined with topical 5-ASA therapy for optimal remission induction. 1

First-Line Treatment Approach

The transverse colon involvement indicates extensive disease that extends beyond the left colon, requiring more aggressive initial therapy than isolated distal disease:

• Start with oral 5-ASA (mesalamine) at high doses (>3g/day): This is the cornerstone of therapy for extensive mild-moderate UC 1

  • Options include: Lialda 2.4-4.8g/day, Delzicol 1.6-4.8g/day, or Asacol HD 1.6-4.8g/day
  • Once-daily dosing is comparable to divided dosing and may improve adherence 1

• Add topical 5-ASA therapy: Combined oral and rectal 5-ASA is superior to oral therapy alone for inducing remission 1

  • Use mesalamine enemas (4g nightly) or suppositories depending on disease extent
  • This combination approach maximizes mucosal drug delivery

Dosing Considerations

The evidence clearly stratifies 5-ASA dosing by effectiveness:

• Low-dose (<2g/day): Insufficient for extensive disease
• Standard-dose (2-3g/day): Adequate for some patients
• High-dose (>3g/day): Preferred for extensive mild-moderate disease 1

If Initial Therapy Fails

For patients not responding to optimal 5-ASA therapy within 2-4 weeks:

1. Add oral budesonide MMX (9mg/day): This provides targeted colonic corticosteroid delivery with fewer systemic side effects than conventional steroids 1

2. Consider short-term systemic corticosteroids: If budesonide is inadequate, use prednisone 40-60mg/day with rapid taper over 8-12 weeks 2, 3

3. Escalate to advanced therapies if corticosteroid-dependent or refractory: Options include TNF antagonists (infliximab, adalimumab, golimumab), vedolizumab, JAK inhibitors (tofacitinib, upadacitinib), or IL-23 inhibitors (ustekinumab, risankizumab) 4

Maintenance Strategy

Once remission is achieved:

• Continue 5-ASA therapy indefinitely at the dose that induced remission 1
• Topical therapy can be reduced to 2-3 times weekly for maintenance
• Do not use corticosteroids for maintenance due to unacceptable side effect profile 1, 2

Critical Pitfalls to Avoid

• Underdosing 5-ASA: Using <3g/day for extensive disease reduces efficacy
• Oral therapy alone: Missing the synergistic benefit of combined oral-topical therapy
• Prolonged corticosteroid use: Never use steroids beyond 3 months; this indicates need for escalation to immunomodulators or biologics 4
• Delayed escalation: If patients fail optimal 5-ASA therapy or become steroid-dependent, promptly advance to biologics or JAK inhibitors rather than continuing ineffective therapy 4

Disease Monitoring

• Assess clinical response at 2-4 weeks
• If achieving remission, perform colonoscopy at 3-6 months to confirm mucosal healing
• Once in remission, surveillance colonoscopy timing depends on risk stratification for dysplasia 5

The key distinction for transverse involvement is recognizing this as extensive disease requiring combination therapy from the outset, not the stepwise approach used for isolated proctitis or left-sided colitis 1.